Market Update: Profusa Closes Merger, Firefly Aerospace Files for US IPO, Tariff Dispute Weighs on Equity Futures

Profusa has completed its merger with NorthView Acquisition, while InflaRx received a Nasdaq deficiency notice due to its minimum bid price. Firefly Aerospace and KBAT Group filed for US IPOs, and Kokobots Group filed for a US IPO of up to 2.5 million class A ordinary shares. S&P and Dow Jones fell as Trump increased tariff pressure on Canada, and Viewbix priced a $4.5 million private placement. Veon and Cohen Circle Acquisition received $52 million in investor backing for their Kyivstar combination.

Profusa, a commercial-stage digital health company, has completed its business combination with NorthView Acquisition Corp. (NVAC) and is set to begin trading on Nasdaq under the ticker symbol "PFSA" on July 14, 2025 [1]. The merger represents a significant milestone for Profusa, which specializes in tissue-integrating biosensors for continuous biochemical monitoring.

As part of the transaction, Profusa has secured $9 million through a secured convertible promissory note from an institutional investor. The funds will be used to cover transaction costs and support future working capital needs, with potential access to up to $20 million under the convertible note facility [1]. This financial arrangement provides Profusa with a substantial runway to advance its technology platform.

Profusa's core technology focuses on tissue-integrating biosensors that can function for extended periods, continuously monitoring and transmitting biochemical data to smartphone applications. The company aims to apply this technology in general health monitoring and the management of specific conditions such as diabetes, critical limb ischemia, and peripheral arterial disease [1].

This public market debut comes after a decade-long development journey for Profusa. The transaction transforms the company's capital structure and potential market visibility, while the company's warrants will continue trading on the OTCID market rather than Nasdaq [1].

For investors, this represents early access to a commercial-stage company in the growing digital health monitoring space, with technology that integrates biochemical sensing, mobile applications, and AI-powered analytics [1].

References:

[1] https://www.stocktitan.net/news/PFSA/profusa-announces-closing-of-business-combination-and-the-tgb6huwepvwh.html